Preventing relapse in recurrent depression using new forms of cognitive therapy: A randomized controlled trial with up to 6 years follow-up

2008 ◽  
Vol 107 ◽  
pp. S97-S98
Author(s):  
C.L.H. Bockting ◽  
Ph. Spinhoven ◽  
A.H. Schene⁎
2015 ◽  
Vol 185 ◽  
pp. 188-194 ◽  
Author(s):  
Claudi L.H. Bockting ◽  
N. Heleen Smid ◽  
Maarten W.J. Koeter ◽  
Philip Spinhoven ◽  
Aaron T. Beck ◽  
...  

2005 ◽  
Vol 73 (4) ◽  
pp. 647-657 ◽  
Author(s):  
Claudi L. H. Bockting ◽  
◽  
Aart H. Schene ◽  
Philip Spinhoven ◽  
Maarten W. J. Koeter ◽  
...  

Pain Medicine ◽  
2019 ◽  
Vol 20 (11) ◽  
pp. 2134-2148 ◽  
Author(s):  
Melissa A Day ◽  
L Charles Ward ◽  
Dawn M Ehde ◽  
Beverly E Thorn ◽  
John Burns ◽  
...  

AbstractObjectiveThis pilot trial compared the feasibility, tolerability, acceptability, and effects of group-delivered mindfulness meditation (MM), cognitive therapy (CT), and mindfulness-based cognitive therapy (MBCT) for chronic low back pain (CLBP).SettingUniversity of Queensland Psychology Clinic.SubjectsParticipants were N = 69 (intent-to-treat [ITT] sample) adults with CLBP.DesignA pilot, assessor-blinded randomized controlled trial.MethodsParticipants were randomized to treatments. The primary outcome was pain interference; secondary outcomes were pain intensity, physical function, depression, and opioid medication use. The primary study end point was post-treatment; maintenance of gains was evaluated at three- and six-month follow-up.ResultsRatings of acceptability, and ratios of dropout and attendance showed that MBCT was acceptable, feasible, and well tolerated, with similar results found across conditions. For the ITT sample, large improvements in post-treatment scores for pain interference, pain intensity, physical function, and depression were found (P < 0.001), with no significant between-group differences. Analysis of the follow-up data (N = 43), however, revealed that MBCT participants improved significantly more than MM participants on pain interference, physical function, and depression. The CT group improved more than MM in physical function. The MBCT and CT groups did not differ significantly on any measures.ConclusionsThis is the first study to examine MBCT for CLBP management. The findings show that MBCT is a feasible, tolerable, acceptable, and potentially efficacious treatment option for CLBP. Further, MBCT, and possibly CT, could have sustained benefits that exceed MM on some important CLBP outcomes. A future definitive randomized controlled trial is needed to evaluate these treatments and their differences.


2019 ◽  
Vol 88 (4) ◽  
pp. 244-246 ◽  
Author(s):  
Naoki Yoshinaga ◽  
Kazumi Kubota ◽  
Kensuke Yoshimura ◽  
Rieko Takanashi ◽  
Yasushi Ishida ◽  
...  

2018 ◽  
Vol 49 (3) ◽  
pp. 465-473 ◽  
Author(s):  
Lotte H.J.M. Lemmens ◽  
Suzanne C. van Bronswijk ◽  
Frenk Peeters ◽  
Arnoud Arntz ◽  
Steven D. Hollon ◽  
...  

AbstractBackgroundAlthough equally efficacious in the acute phase, it is not known how cognitive therapy (CT) and interpersonal psychotherapy (IPT) for major depressive disorder (MDD) compare in the long run. This study examined the long-term outcomes of CT v. IPT for MDD.MethodsOne hundred thirty-four adult (18–65) depressed outpatients who were treated with CT (n = 69) or IPT (n = 65) in a large open-label randomized controlled trial (parallel group design; computer-generated block randomization) were monitored across a 17-month follow-up phase. Mixed regression was used to determine the course of self-reported depressive symptom severity (Beck Depression Inventory II; BDI-II) after treatment termination, and to test whether CT and IPT differed throughout the follow-up phase. Analyses were conducted for the total sample (n = 134) and for the subsample of treatment responders (n = 85). Furthermore, for treatment responders, rates of relapse and sustained response were examined for self-reported (BDI-II) and clinician-rated (Longitudinal Interval Follow-up Evaluation; LIFE) depression using Cox regression.ResultsOn average, the symptom reduction achieved during the 7-month treatment phase was maintained across follow-up (7–24 months) for CT and IPT, both in the total sample and in the responder sample. Two-thirds (67%) of the treatment responders did not relapse across the follow-up period on the BDI-II. Relapse rates assessed with the LIFE were somewhat lower. No differential effects between conditions were found.ConclusionsPatients who responded to IPT were no more likely to relapse following treatment termination than patients who responded to CT. Given that CT appears to have a prophylactic effect following successful treatment, our findings suggest that IPT might have a prophylactic effect as well.


Sign in / Sign up

Export Citation Format

Share Document